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Abstract
Objective Limited evidence is available on predictors of
medical resource utilization (MRU) and related direct
costs, especially in treatment-experienced patients infected
with genotype 1 hepatitis C virus (HCV). This study aimed
at investigating patient and treatment characteristics that
predict MRU and related non-drug costs in treatment-ex-
perienced patients with chronic hepatitis C (CHC) treated
with simeprevir (SMV) or telapravir (TVR) in combination
with pegylated interferon and ribavirin (PegIFN/R).
Patients and Methods A total of 709 patients who com-
pleted the 72-week ATTAIN trial were included in the
study. Cost data were analysed from the UK NHS per-
spective. Descriptive statistics and regression analyses
were used to determine patterns and predictors of total
MRU-related costs associated with SMV/PegIFN/R and
TVR/PegIFN/R.
Results Independent predictors for total MRU-related
costs were age, region and the following interaction terms:
(1) gender 9 F3–F4 METAVIR score 9 baseline viral
load (BLVL), (2) body mass index (BMI) 9 F3–F4
METAVIR score 9 prior response to PegIFN/R and (3)
gender 9 achievement of SVR at 12 weeks
(SVR12) 9 BLVL. A F3–F4 METAVIR score was a
stronger predictor of total MRU-related costs than SVR12.
Predictors of adverse events included older age, female
gender, low BMI, TVR/PegIFN/R and SVR12. Wilcoxon
rank sum test revealed comparable total MRU-related costs
between SMV/PegIFN/R and TVR/PegIFN/R.
Conclusion To the best of our knowledge, this study is
the first to describe the relationship between commonly
admitted predictors of MRU-related costs and their joint
effect on total MRU-related costs in treatment-experienced
patients with CHC. The identified predictors of MRU-re-
lated costs suggest that significant treatment costs can be
avoided by starting treatment early before the disease
progresses. Furthermore, adverse events seem to be the
most important factor to take into consideration for the
choice of treatment, especially when therapeutic options
are associated with similar levels of medical resource uti-
lization and associated costs.
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Key Points
Early age identification and treatment of patients
with hepatitis C infection would limit non-response
and advanced liver disease and associated non-drug-
related costs. A weight-loss programme should
further be considered in the management of
treatment-experienced patients with chronic hepatitis
C.
The achievement of a sustained virologic response at
week 12 is associated with significant reduction in
non-drug-related costs, an effect that is strongly
dependent on both liver disease severity and baseline
viral load. This study advocates for a close
monitoring of liver disease fibrosis together with
(and not independently from) baseline viral load
when caring for treatment-experienced patients with
chronic hepatitis C.
Finally, in clinical practice, the choice of treatment
for experienced patients with chronic hepatitis C
should be guided primarily by the safety profile and
the risk of adverse events of the direct-acting
antiviral agents.
1 Introduction
Hepatitis C virus (HCV) is the leading cause of chronic
hepatitis C (CHC), liver cirrhosis, hepatocellular carcinoma
and liver transplantation [1, 2]. HCV infection accounts for
33 % and 20 % of total liver cancer in developing and
developed countries, respectively [3]. Hence, CHC is
acknowledged as a major public health problem. The disease
burden of HCV in Europe is currently at its peak given the
prolonged time-course of the condition—individuals that
were infected in the 1980s (when the disease propagation
outbreak was significant) are currently developing cirrhosis
[4, 5]. The clinical management requires efficacious drugs
that stop the progression of the disease and reduce the
number of HCV-infected patients that could potentially
develop complications. Consequently, the limitations of the
dual therapy pegylated interferon plus ribavirin (PegIFN/R,
former standard of care) and of the first generation of direct-
acting agents [telaprevir (TVR) and boceprevir (BCP)]
prompted the development of new therapies including
simeprevir (SMV) with improved tolerability, applicability
and compliance profiles as compared to TVR triple therapies
(i.e., in combination with PegIFN/R) [6–9]. As new regi-
mens may come at a higher price, decision makers also need
to understand patient and treatment characteristics that
influence resource use, and thus the total healthcare costs.
This is shown by the cost effectiveness of new antiviral
drugs that can be further improved by efficient use and
savings in medical resources. Although it should be noted
that drug costs, in particular direct-acting agents, constitute
80–90 % of the total direct cost [10–13] and about 50 % of
the total direct and indirect costs [14] in patients with CHC.
Understanding the parameters associated with high health-
care costs may then be useful in improving efficiency in care
delivery for patients with high-cost CHC. This is particularly
relevant for disease management programmes aiming at
improving the welfare of patients with chronic conditions
that generally consume more healthcare services, including
physician visits, specialist visits and hospital care [15, 16].
Backx et al. recently quantified the medium-term dif-
ference in medical resource utilization (MRU) and related
costs based on response status to PegIFN/R treatment [17].
They reported per patient per year non-drug costs of £806
and £506 for retreated and non-retreated patients with
CHC, respectively. The additional non-drug-related costs
for the retreated patients were mainly attributable to
increased numbers of outpatient visits and HCV RNA tests
related to treatment monitoring. Consequently, care for
patients with CHC who failed to achieve a sustained
virologic response (SVR, a marker of viral clearance and of
cure) places a significant economic burden on health ser-
vices [18]. However, the existing literature poorly charac-
terizes factors that predict high and low MRU and related
costs, especially in treatment-experienced patients infected
with genotype 1 HCV. The purpose of this study was to
determine whether a significant relationship exists between
baseline demographics, clinical characteristics and treat-
ment features and non-drug MRU-related costs among
treatment-experienced patients. Medical resource data
collected alongside the ATTAIN pivotal trial (Simeprevir
vs Telaprevir with Peginterferon and Ribavirin in Previous
Null or Partial Responders with Chronic Hepatitis C Virus
Genotype 1 Infection) were used for this purpose. In
addition, this study looked at how SMV/PegIFN/R and
TVR/PegIFN/R affected MRU and associated costs.
2 Methods
2.1 Study Design
The ATTAIN trial was a phase III, randomized, double-
blind, non-inferiority trial set up to evaluate the efficacy,
safety and tolerability of SMV/PegIFN/R versus TVR/
PegIFN/R triple regimens in CHC genotype 1 infected
patients who were prior partial or null responders to
PegIFN/R therapy. The study comprised a 48-week
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treatment phase followed by a post-therapy period up to
72 weeks after the start of the treatment. MRU data were
collected alongside the trial and included hospitalization
days, nights in the intensive care unit as well as emergency
room, gastroenterologist, hepatologist, psychiatrist, psy-
chologist, infectious disease specialist, nurse, primary care
physician, surgeon, social worker, home and other (phys-
iotherapist) visits.
2.2 Cost Data
The UK NHS perspective was considered to estimate
MRU-related unit costs. Unit costs for each resource were
derived from NHS reference costs [19] or the ‘Unit Costs
of Health and Social Care’ from the Personal Social Ser-
vices Research Unit (PSSRU) [20, 21]. Costs were inflated
to 2014 values using the medical component of the Con-
sumer Price Index [22]. The unit costs are summarized in
Table 1. The total MRU-related cost per patient was cal-
culated by multiplying each resource by its unit costs and
then summing the individual MRU-related costs for each
patient or treatment arm. Thus, this study applies only to
service care provision, as costs related to tests, procedures
and medications were not analysed.
2.3 Statistical Analyses
2.3.1 Dataset
The analysis was based on the 72-week study period that
included treatment and follow-up phases. For each patient,
data on demographics [age, gender, geographical region
and baseline body mass index (BMI)], clinical character-
istics [baseline viral load (BLVL), IL28B polymorphism,
F3–F4 fibrosis score, prior response to PegIFN/R] and
treatment features [treatment status (SMV/PegIFN/R vs
TVR/PegIFN/R), SVR12 achievement and adverse events]
were gathered. With respect to treatment features, adverse
events encompassed anaemia, bilirubin, neutropenia, pru-
ritus, rash and absence of any of these adverse events. An
additional categorical variable level was created to account
for joint occurrences or potential interactions between each
of the selected adverse events and the others. Capturing
first-order to fourth-order interactions would have entailed
an additional 20 covariates, which could result in conver-
gence issues. Patients with missing data and total MRU-
related cost outliers were excluded from the analysis. To
identify outliers, a simple ordinary least square (OLS)
regression was fitted to total MRU-related costs while
controlling for all factors. Total MRU-related costs with
Table 1 Unit cost per medical
resource (£, UK tariff)









Emergency room visit 122.00 33.00 130.57 35.32
Gastroenterologist visit 164.00 45.00 175.52 48.16
Hepatologist visit 216.00 27.00 231.17 28.90
Infectious disease specialist visit 280.00 164.00 299.67 175.52
Psychiatrist visit 178.00 178.00 190.50 190.50
Psychologist visit 56.00 157.00 59.93 168.03
Surgeon visit 145.00 112.00 155.18 119.87
Home visit 70.00 29.00 74.92 31.04
Nurse visit 21.00 21.00 22.47 22.47
Night in intensive care unit 868.00 868.00 928.96 928.96
Primary care physician visita 54.00 54.00 63.71 63.71
Social worker visita 30.00 30.00 35.39 35.39
Night in hospitalb 235.00 235.00 287.30 287.30
Other visitc 43.00 - 46.02 -
Tariff data were taken from National Schedule of Reference Costs 2011–2012 unless stated otherwise
a Curtis L. Unit Costs of Health and Social Care 2008. Personal Social Services Research Unit (PSSRU),
University of Kent, 2008
b Curtis L. Unit Costs of Health and Social Care 2007. Personal Social Services Research Unit (PSSRU),
University of Kent, 2007
c A conservative estimate of the unit costs for physiotherapy was applied because the majority of ‘other
visits’ were related to physiotherapy and other types of visits in this category were typically more expensive
Direct Medical Costs for HCV Infection 337
studentized statistical residue outside the range -2 to 2
were considered as outliers and removed from the database.
2.3.2 Data Analysis
A two-step approach was undertaken to tackle the objective
of the study. The first step consisted of determining the
relationship between total MRU-related costs and each of
the various patient and treatment variables. Analysis of
variance and simple OLS regressions were used for cate-
gorical and continuous variables, respectively. For those
categorical variables that showed significance at the 5 %
level, Tukey’s HSD (honestly significant difference) post
hoc test was used to detect where the difference lies
between levels. Multivariable regression was then used in a
second step to provide the independent contribution of each
of the patient and treatment variables to the prediction of
total MRU-related costs. For that, variables with linear
effects were used as explanatory variables in a stepwise
multiple OLS regression that aimed at determining the
strongest and most effective predictors of total MRU-re-
lated costs. The rationale behind the use of OLS regression,
despite the skewed distribution of total MRU-related cost
data, was that inferences could be made about the arith-
metic mean; the most informative measures for healthcare
policy decision makers [23].
Checks were then performed to validate the results of
the multivariable regression analyses, including non-para-
metric bootstrapping to assess the robustness of confidence
intervals and p values to non-normality in the total MRU-
related costs distribution [24]. Additionally, results of the
multivariable OLS regression models were systematically
compared with those obtained from a stepwise generalized
linear model (GLM) where a gamma distribution was
assumed for total MRU-related costs. Of note, this vali-
dation exercise takes into account only patients with a
positive cost [25]. Chi-square statistics were used to vali-
date GLM models, and descriptive statistics and Wilcoxon-
rank sum test conducted to compare the pattern of MRU-
related costs between SMV/PegIFN/R and TVR/PegIFN/R.
Co-linearity between independent variables was evalu-
ated through the calculation of the variance inflation factor
(VIF). A VIF score [2 was taken as an indication of
multicollinearity in multivariable regressions. p values
associated with regression coefficients between 1 % and
5 % were considered at the borderline of statistical sig-
nificance; an indication of possible interaction with other
variables. These potential interactions between variables
and the extent to which they were associated with total
MRU-related costs were further investigated. Finally, to
provide further insight into the interaction effects, a series
of stepwise OLS, logistic and multinomial regression
analyses was conducted for numeric, two-level and more
than two-level categorical variables, respectively. Statisti-




The intention-to-treat (ITT) population included 763 prior
non-responders to PegIFN/R. Data screening for outliers
resulted in excluding 18 data points. The removal of the
outliers was deemed appropriate given that the adjusted R2
of the two OLS models fitted to the total MRU-related
costs (one model including the outliers, the other not) were
virtually similar (data not shown). Thirty-six patients with
incomplete data were further excluded from the analysis.
The final set of 709 patients was then used to compute
regression models and descriptive statistics for MRU-re-
lated costs. This is equal to 93 % of the ITT population.
3.2 Total MRU-Related Costs
For the entire trial population, total MRU-related costs per
patient averaged £363.34 ± standard deviation (SD):
£746.45; median: £63.71; interquartile range (IQR):
£318.53; indicating positive skewness of the costs (Fig. 1).
To determine the resources that contributed the most to
total MRU-related costs, univariate OLS regression anal-
yses were fitted to total MRU-related costs while control-
ling for each type of medical resources. The variation in
total MRU-related costs was found to be mainly
attributable to nights in hospital (63 %, data not shown).
Fig. 1 Histogram of total medical resource utilization (MRU)-related
costs (£) for the prior non-responders to pegylated interferon and
ribavirin (PegIFN/R) in the ATTAIN trial. The x axis represents the
range of non-drug total MRU-related costs, calculated as follows: unit
costs for each of the selected resources were multiplied by the number
of visits made by each patient. Costs across the medical resources
were then summed up for each of the patients. Costs were then
grouped into ten bins and frequency calculated accordingly
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3.3 Univariate Predictors of Total MRU-Related
Costs and Interaction Terms
To identify patient demographics (clinical characteristics
and treatment features that can influence total MRU-related
costs), univariate analyses were performed. The results
from this analysis are shown in Table 2. For patient
demographics, higher costs were found to be significantly
associated with higher age (p\ 0.001). Each additional
year of age was associated with an average increase of
£8.98 in total MRU-related costs. In addition, differences
were found across the various regions (p\ 0.05). Tukey’s
HSD analyses revealed higher costs in North America
compared with South American regions, with a mean dif-
ference of £326.91 (p\ 0.05, data not shown). Gender and
BMI were found to be at the borderline significance level in
their contribution to explaining the variation in costs
(p\ 0.1). For the clinical characteristics, patients with
severe liver fibrosis (F3–F4 METAVIR score) incurred
higher costs than those with mild to moderate liver fibrosis
(F0–F2 METAVIR score), with a mean difference of
£198.21 (Tukey’s HSD test, p\ 0.001). Finally, for the
treatment features, the association between SVR12 and
costs was borderline significant.
After identifying interaction effects, the variables that
showed borderline significance levels (gender, BMI and
SVR12) were further investigated. However, prior to
studying these interactions through multivariable regres-
sion analyses, tests for multicollinearity were conducted.
Results revealed VIF values\2, indicating that significant
multicollinearity was not present in the selected predictor
variables.
For the interactions between gender and any other
covariates, multivariable OLS regression with total MRU-
related costs as the dependent variable did not reveal sig-
nificant first-order interaction effects. However, significant
second-order interaction effects were identified between
gender 9 F3–F4 9 BLVL (p\ 0.05) (data not shown).
For the interactions between BMI and any other
covariates, no significant first-order interaction effects were
found, although BMI 9 F3–F4 was found to be borderline
significant (data not shown). Subsequent examination led
to identification of the following three second-order inter-
action terms: BMI 9 F3–F4 9 prior response to PegIFN/R
(p\ 0.05), BMI 9 F3–F4 9 therapy (p\ 0.1) and
BMI 9 F3–F4 9 region (p\ 0.05). The model with the
interaction term BMI 9 F3–F4 9 therapy did not yield to
higher predictive power than the one with only the inter-
action term BMI 9 F3–F4. Therefore, the second model
was rejected and no third-order interaction was investi-
gated. With the BMI 9 F3–F4 9 region model, the rela-
tively large standard error of the coefficient and the small
number of the Asian-Pacific patients limited the confidence
in this finding and led also to the rejection of this model
(data not shown).
For the interactions between SVR12 and any other
covariates, the coefficient associated with the second-order
interaction term gender 9 SVR12 9 BLVL was found to
be significant at the 5 % level (data not shown).
Overall, the results described above were confirmed by
GLM models with a gamma log link function fitted to total
MRU-related costs with the same set of predictors. In
summary, age, region and the interaction terms gen-
der 9 F3–F4 9 BLVL, BMI 9 F3–F4 9 prior response
to PegIFN/R and gender 9 SVR12 9 BLVL were signif-
icantly associated with total MRU-related costs.
3.4 Multivariable Predictors of Total MRU-Related
Costs
The independent contribution of the predictors that showed
significant univariate correlation to total MRU-related
costs was examined next. Stepwise multivariable OLS and
GLM regression models were fitted to total MRU-related
costs while controlling for the following variables: age,
region and the interaction terms gender 9 F3–F4 9
BLVL, BMI 9 F3–F4 9 prior response to PegIFN/R and
gender 9 SVR12 9 BLVL. The coefficients of the fol-
lowing variables and interaction terms were significantly
different from zero in the multivariable OLS (Table 3) and
GLM (Table S1, see electronic supplementary material
[ESM]) models: age (p\ 0.05), region (South America)
(p\ 0.05), gender (male) 9 F3–F4 (Yes) 9 BLVL
(p\ 0.05), and BMI 9 F3–F4 (Yes) 9 prior response to
PegIFN/R (partial responder) (p\ 0.05). The second-order
interaction term gender (male) 9 SVR12 (yes) 9 BLVL
was not detected as significant.
Table 3 indicates that there was an average increase of
£5.86 in total MRU-related costs for each additional year in
patient’s age (p\ 0.05). With the interaction terms, a
reduction of £64.90 on average total MRU-related costs
was observed in prior partial responders to PegIFN/R with
severe liver fibrosis compared with equivalent prior null
responders across BMI values. Similarly, a reduction of
£49.36 on average total MRU-related costs was identified
in male patients with severe liver fibrosis compared with
equivalent female patients across BLVL values. With
respect to the variable region, analyses showed that total
MRU-related costs tend to be reduced by £223.60 on
average in South America compared with Europe
(p\ 0.05). The coefficient associated with the interaction
term gender (male) 9 SVR12 (yes) 9 BLVL was not
significantly different from zero in both the OLS and GLM
models, and age was not detected in the GLM model.
In summary, age, region and interaction effects between
gender, F3–F4, BLVL, BMI and prior response to PegIFN/
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Table 2 Univariate predictors
of total MRU-related costs
N £ Mean MRU-related costs (£ standard deviation) P value
a) Results of analysis of variance for categorical variables
Gender \0.1c
Female 276 425.45 (844.27)
Male 433 323.75 (674.83)
Region \0.05
Asia-Pacific 16 609.97 (769.68)
Europe 513 351.07 (751.89)
North-America 110 503.51 (829.32)
South-America 70 176.61 (474.95)
IL28B 0.661
CC 32 333.93 (557.08)
CT 462 381.99 (793.62)
TT 215 327.64 (662.96)
Treatment status 0.585
Simeprevir 350 347.84 (731.41)
Telaprevir 359 378.46 (761.55)
F3-F4 \0.001
No 440 288.14 (606.54)
Yes 269 486.34 (919.17)
Prior response 0.641
Null responder 435 373.72 (772.09)
Partial responder 274 346.85 (704.91)
SVR12 \0.1c
No 328 419.69 (809.47)
Yes 381 314.83 (684.97)
Adverse events 0.288
Anaemia 64 334.77 (719.41)
Bilirubin 7 567.69 (575.77)
Multiple adverse events 298 443.26 (807.88)
Neutropenia 44 299.07 (618.37)
Pruritus 97 332.49 (710.56)
Rash 33 246.42 (545.87)
Other adverse eventsa 166 280.58 (728.19)
N Mean MRU-related costs (standard deviation) P valueb R2 (%)
b) Results of linear regression for continuous variables
Age \0.001 1.641
Age\ 51 343 266.65 (635.80)
Age C 51 366 453.95 (827.65)
Baseline body mass index (BMI) \0.1c 0.442
BMI\ 26.4 351 334.90 (694.03)
BMI C 26.4 358 391.22 (794.49)
Baseline viral load (BLVL) 0.303 0.150
BLVL\ 3,650,000 354 380.15 (752.62)
BLVL C 3,650,000 355 346.58 (740.93)
Results for continuous variables are presented in two groups split at the median value, though regression analyses were
performed on the entire set of data
BLVL baseline viral load in per million IU/mL, BMI body mass index in kg/m2, MRU medical resource utilization, SVR12
sustained virologic response at week 12
a Other adverse events correspond to any adverse event except anaemia, neutropenia, pruritus and rash and their
combinations
b p values associated with linear regression for continuous variables are those of the regression models
c p value at the borderline of the 5 % significance level
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R were identified as the most parsimonious set of predic-
tors for total MRU-related costs. Bootstrap regression
analyses also confirmed the outcome of the multivariable
OLS regression model.
3.5 Effect of the Interaction Terms
Two approaches were used to gain insight into the inter-
action terms. First, simple effects (i.e. the effect of one
independent variable at fixed values of the others) were
calculated. For this purpose, stepwise multivariable OLS
and logistic regression models were fitted to numeric and
categorical variables captured in second-order interaction
terms, while controlling for other patient demographics and
treatment features. Age and region were also included in
the assessment.
A Stepwise logistic regression analysis using gender as
the dependent variable revealed significant correlations of
this variable with BLVL and adverse events (Table S2, see
ESM). The odds of experiencing anaemia [odds ratio (OR)
0.20; 95 % CI 0.10–0.37; p\ 0.001] and multiple adverse
events (OR 0.39; 95 % CI 0.26–0.59; p\ 0.001) was
lower in male than in female patients. The likelihood of
having high BLVL values was similar between genders. A
borderline significant correlation was observed between
age and male gender, suggesting that the male patients
were a bit older than the female patients in our sample.
A stepwise multivariable logistic regression with F3–F4
as the dependent variable revealed three main factors:
SVR12, age and BMI (Table S3, see ESM). Patients with
severe liver fibrosis (F3–F4) had a lower chance of
achieving SVR12 compared with those with mild to
moderate liver fibrosis (F0–F2; OR 0.63; 95 % CI
0.46–0.86; p\ 0.01). Likewise, higher age and higher BMI
were associated with higher odds of developing severe
liver fibrosis (F3–F4): OR 1.06 (95 % CI 1.04–1.07;
Table 3 Multivariable
predictors of non-drug total
MRU-related costs
Estimate Standard error p value
Intercept -127.702 295.913 0.666
Age 5.863 2.769 \0.05
SVR12 (yes) 72.339 124.606 0.562
Gender (male) -90.826 142.968 0.526
BLVLa -6.096 14.340 0.671
F3–F4 (yes) 201.502 435.020 0.643
BMIa 6.661 10.128 0.511
Prior response to PegIFN/R (partial responder) -634.333 452.622 0.162
Region (North America) 65.032 81.907 0.428
Region (South America) -223.602 93.597 \0.05
Region (Asia–Pacific) 196.021 184.983 0.290
SVR12 (yes): gender (male) -75.284 159.496 0.637
SVR12 (yes): BLVL 4.527 16.465 0.783
Gender (male): BLVL 31.297 17.297 0.071
Gender (male): F3–F4 (yes) 76.563 164.500 0.642
BLVL: F3–F4 (yes) 13.921 15.767 0.378
F3–F4 (yes): BMI -1.293 15.195 0.932
BMI: prior response (partial response) 21.032 16.796 0.211
F3–F4 (yes): prior response (partial response) 1869.356 731.496 \0.05
Gender (male): SVR12 (yes): BLVL -32.336 20.469 0.115
Gender (male): F3-F4 (yes): BLVL -49.356 21.578 \0.05
BMI: F3-F4 (yes): prior response (partial response) -64.904 26.568 \0.05
A stepwise multivariable OLS regression model was fitted to total MRU-related costs while controlling for
the following factors: age, region, baseline BMI 9 F3–F4 9 prior response to PegIFN/R, gender 9 F3–
F4 9 BLVL and gender 9 SVR12 9 BLVL. Interaction terms were identified in univariate analyses as
factors with linear effects on total MRU-related costs. The outcome of the present analysis was further
confirmed by a generalized linear model where a gamma distribution was assumed for total MRU-related
costs
BMI body mass index, BLVL baseline viral load, MRU medical resource utilization, OLS ordinary least
square, PegIFN/R pegylated interferon and ribavirin, SVR12 sustained virologic response at week 12
R2 = 0.088, p\ 0.001
a BLVL in per million IU/mL, BMI in kg/m2
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p\ 0.001) and 1.05 (95 % CI 1.01–1.08; p\ 0.05),
respectively.
A stepwise multivariable logistic regression with prior
response to PegIFN/R as the dependent variable revealed a
significant correlation with SVR12 and IL28B (Table S4,
see ESM). Prior partial responders to PegIFN/R were more
likely to achieve SVR12 than prior null responders (OR
2.85; 95 % CI 2.06–3.94; p\ 0.001). With an OR of 2.43
(95 % CI 1.13–5.23), prior partial responders to PegIFN/R
were more likely to have the CC genotype than prior null
responders to PegIFN/R (p\ 0.05). Borderline signifi-
cance was observed between age and prior partial respon-
ders to PegIFN/R, indicating that this subgroup tends to be
older than the prior null responders subgroup in our
sample.
The variables that proved to be strongly associated with
SVR12 in a stepwise multivariable logistic regression were
region, prior response to PegIFN/R, F3–F4 and adverse
events (Table S5, see ESM). Results related to prior
response to PegIFN/R and F3–F4 were confirmed in pre-
vious analyses (Table S3, S4, see ESM). North American
treatment-experienced patients were less likely to achieve
SVR12 compared with European ones (OR 0.50; 95 % CI
0.32–0.78; p\ 0.05). For patients who achieved SVR12,
there was an increase in the odds of having multiple
adverse events (OR 2.04; 95 % CI 1.36–3.06; p\ 0.01) or
neutropenia (OR 2.74; 95 % CI 1.32–5.66; p\ 0.01).
Borderline significance was further found between SVR12
and South America, anaemia or pruritus.
Age, BMI and SVR12 were found to be significantly
correlated to region in a stepwise multinomial regression
analysis (Table S6, see ESM). Older patients in the selected
population were more likely to be North American patients
than European patients [relative risk (RR) 1.06; 95 % CI
1.03–1.09; p\ 0.001]. North American patients were also
more likely to have a higher BMI than European patients
(RR 1.16; 95 % CI 1.11–1.22; p\ 0.001). Finally, North
American (RR 0.48; 95 % CI 0.31–0.75; p\ 0.01) and
South American (RR 0.59; 95 % CI 0.35–0.97; p\ 0.05)
patients were less likely to achieve SVR12 compared with
European patients.
Three additional multivariable OLS regressions were
conducted with age, BMI and BLVL as dependent vari-
ables. Age was significantly associated with F3–F4, BMI,
BLVL and adverse events (Table S7, see ESM). Patients
with severe liver fibrosis (F3–F4) were on average 5 years
older than those with mild to moderate liver fibrosis (F0–
F2; p\ 0.001). Similarly, strong positive correlations
between age and BMI (p\ 0.001) and age and BLVL
(p\ 0.05) were found. Patients with anaemia were on
average 6 years older than those with none of the selected
adverse events (p\ 0.001). The same was true for patients
experiencing multiple adverse events, who were on average
3 years older than those with none of the selected adverse
events (p\ 0.05). It was further found that BMI had a
protective effect against anaemia and multiple adverse
events given that patients who experienced these events
had on average a lower BMI than those who did not
(p\ 0.05) (Table S8, see ESM). Finally, a strong corre-
lation was found between BLVL and age (p\ 0.05) and
IL28B (p\ 0.001) (Table S9, see ESM). Treatment-ex-
perienced patients with the TT genotype had, on average,
two per million IU/mL BLVL lower than those with the CT
genotype.
Interaction effects were also explored graphically.
Figure 2 shows that male patients with severe liver fibrosis
(F3–F4) had a lower BLVL than equivalent female
patients. In addition, patients who were prior null respon-
ders with severe liver fibrosis had higher average BMI than
equivalent patients who were partial responders. This
illustrates that the direction and the magnitude of the cor-
relations with BLVL and BMI can differ significantly by
subgroup.
3.6 Predictors of On-Treatment Adverse Events
The association between adverse events and some of the
predictors of total MRU-related costs prompted the anal-
ysis of the factors associated with on-treatment adverse
events. Figure 3 shows that the occurrence of the selected
adverse events was relatively higher in the TVR/PegIFN/R-
treated group than in the SMV/PegIFN/R-treated group,
and therefore the absence of events was lower. Moreover,




















































Fig. 2 Average baseline viral load in female and male patients with
severe liver fibrosis and average BMI in prior non-responders to
PegIFN/R with severe liver fibrosis. The graph on the left-hand side
captures variables in the second-order gender 9 BLVL 9 F3–F4
interaction term. Average baseline viral load was plotted by gender
levels for patients with severe liver fibrosis. The graph on the right-
hand side captures variables in the F3–F4 9 BMI 9 prior response to
PegIFN/R interaction term. Average baseline BMI is segmented by
levels of prior response to PegIFN/R in patients with severe liver
fibrosis. BMI body mass index, BLVL baseline viral load, PegIFN/R
pegylated interferon and ribavirin
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across all treatment groups than the occurrence of any
single adverse event. Multiple adverse events among
female patients treated on TVR/PegIFN/R were the most
commonly observed events. Further investigation of the
factors associated with adverse events through multinomial
regression analyses revealed that the risk of experiencing
anaemia (RR 2.53; 95 % CI 1.37–4.68), pruritus (RR 2.39;
95 % CI 1.43–4.00), rash (RR 2.72; 95 % CI 1.26–5.87)
and multiple adverse events (RR 2.54; 95 % CI 1.69–3.81)
was significantly higher in the TVR/PegIFN/R arm than in
the SMV/PegIFN/R arm (Table 4). In agreement with the
simple effect analysis of the interaction terms, the corre-
lations between age, gender, BMI, SVR12 and adverse
events were further confirmed.
3.7 Comparison of Total MRU-Related Costs
Between SMV/PegIFN/R and TVR/PegIFN/R
Previous analyses did not identify treatment status as an
explanatory variable explaining the variation in total
MRU-related costs. Therefore, descriptive statistics and a
Wilcoxon rank sum test were used to compare MRU-
related costs between SMV/PegIFN/R and TVR/PegIFN/
R. In line with the result from the regression analysis, no
significant difference could be found for the median total
MRU-related costs between the two treatment regimens
(Table S10, see ESM). The same was observed for each
of the 13 sub-types of medical resource. None of the
patients stayed in intensive care unit. Additionally, when
considering only patients with a positive cost, no differ-
ence in total MRU-related costs was detected. Overall,
median total MRU-related costs (IQR) among all patients
treated with SMV/PegIFN/R and all patients treated with











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 3 Distribution of SVR12 achievers by therapy, gender and
adverse events. Absence refers to patients that did not report any of
the selected adverse events (i.e. anaemia, bilirubin, neutropenia,
pruritus and rash). PegIFN/R pegylated interferon and ribavirin
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4 Discussion
SMV, a second generation of direct-acting antiviral HCV,
led to high cure rates among patients who had previously
failed with PegIFN/R. In the ATTAIN study, a pivotal trial
comparing SMV/PegIFN/R with TVR/PegIFN/R, one of
the first proteinase inhibitors, MRU-related data were
collected to get further insights in care provision to prior
non-responder patients. Among the evaluated resources
was hospitalization, which accounted for the largest share
of the total MRU-related costs. Savings from reduced
hospitalization could potentially provide room to further
optimize treatment for patients with CHC. The present
study shows how patient demographics, clinical charac-
teristics and treatment features were associated with MRU-
related costs for treatment-experienced patients infected
with CHC.
4.1 Patient Demographics and Clinical Factors
as Predictors of Total MRU-Related Costs
Of the demographic variables included in the analysis, age
was found to be significantly associated with total MRU-
related costs in univariate analyses; and with clinical fac-
tors and treatment features when evaluating interaction
terms. Similarly, Gordon et al. found through a retrospec-
tive analysis of a medical and pharmacy claims database
that an increase in direct healthcare costs associated with
CHC corresponds with increasing age and disease severity
[26]. Also, Razavi et al. showed higher costs in patients
experiencing decompensated cirrhosis [27]. Our results
further align with what was previously reported in the lit-
erature; that is, progression to cirrhosis is associated with
older age and high BMI [28–31], which leads to additional
costs. This finding underlines the importance of closely
monitoring disease progression in older patients. Older
patients are exposed to many debilitating conditions such
as arthritis, depression, fatigue and anaemia; conditions
with symptoms that also accompany CHC. Hence, detect-
ing CHC might be challenging in older patients, given the
underestimation of its true prevalence among aged patients,
who are more likely to develop advanced liver disease [32,
33]. Observations from other studies reported that anaemic
patients were more likely to be older, to be female and to
have lower BMI [34–36].
Male gender was also identified as a predictor of total
MRU-related costs when included in interaction with F3–
F4 and BLVL, and with SVR12 and BLVL. Multivariable
logistic regression with F3–F4 as the dependent variable
indicated that advanced fibrosis strongly affects the likeli-
hood of achieving SVR12. In a study investigating the
efficacy and safety profiles of PegIFN/R in older patients
with chronic hepatitis C, Oze et al. reported that the pro-
gression of liver fibrosis or the decrease of drug exposure
concomitant with age could account for the reduction of
SVR rate among these patients [37]. Using univariate and
multivariable analyses to determine the factors associated
with high SVR24 rates in a cohort of treatment-naı¨ve and
prior non-responder patients that received TVR/PegIFN/R,
Colombo et al. identified the following predictors of
SVR24: bridging fibrosis, genotype 1b, any previous
response other than null response, baseline viral load
(\800,000 IU/mL) and alpha fetoprotein concentration
(\10 lg/L) [38, 39]. Our results confirm that patients who
achieve SVR12 consume less medical resources; an effect,
however, dependent on BLVL and liver fibrosis stage in
treatment-experienced patients. This probably explains
why the interaction term gender 9 SVR12 9 BLVL was
no longer significant in multivariable regression analysis
upon the inclusion of the interaction term gender 9 F3–
F4 9 BLVL. F3–F4 is likely a stronger predictor than
SVR12 on the MRU-related costs, and diminished its
effect. This is clear from the strong correlation between
F3–F4 and SVR12.
In the currently studied population, total MRU-related
costs were significantly lower in male patients with F3–F4
METAVIR score and low BLVL compared with their
equivalent female patients with high BLVL. Consequently,
it is important to monitor liver disease severity and BLVL
together and not independently as these parameters can
reduce total MRU-related costs significantly when patients
with CHC are treated early. Such an outcome has sub-
stantial implications when evaluating, for example, treat-
ment strategies against HCV before and after liver
transplantation in patients with advanced liver fibrosis [40].
It has been reported that spontaneous clearance of HCV
after transplantation is rare while reinfection of the allo-
graft is common; therefore reducing the prognosis of these
patients [41–44]. Adopting antiviral drugs that could
eradicate the virus from the bloodstream and reduce the
risk of reinfection of the allograft could then potentially
generate substantial savings in MRU-related costs and
improve the condition of the patient.
The second interaction effect on total MRU-related costs
was BMI 9 F3–F4 9 prior response to PegIFN/R. This
result confirms the positive correlation between high BMI,
the pathogenesis of steatosis and fibrosis, and the fact that
high BMI has been reported to be an independent risk
factor for non-response to antiviral therapy [45–47]. It
might not be surprising to observe lower total MRU-related
costs in prior partial responders than in prior null respon-
ders to PegIFN/R with severe liver fibrosis. This is the
consequence of (1) higher BMI and older age being asso-
ciated with severe liver fibrosis, (2) patients with severe
liver fibrosis being less likely to achieve SVR than those
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with mild to moderate liver fibrosis and (3) in the current
setting, the average BMI being lower in prior partial
responders with F3–F4 METAVIR stage than their equiv-
alent null responders to PegIFN/R. Loss of weight should
thus be considered when treating prior non-responders to
PegIFN/R with advanced liver fibrosis.
Region was further detected as a predictor of total
MRU-related costs. South American patients showed lower
total MRU-related costs than European patients. Number of
visits to a physiotherapist and associated costs were higher
among South American than European patients whereas
the number of visits to the primary care physician were
lower among South American patients compared with
European patients (data not shown). The higher unit cost
for primary-care physician visits than for physiotherapist
visits explains why lower MRU-related costs were
observed among South American patients. This indicates
that patients’ access to specialists is to be taken into con-
sideration to manage non-drug MRU-related costs.
This study has also identified factors predictive of
adverse events in prior non-responders to PegIFN/R treated
with SMV/PegIFN/R and TVR/PegIFN/R. Female gender,
older age and low BMI were predictors of anaemia; an
observation confirmed in previous publications and irre-
spective of naı¨ve and experienced treatment populations
[34–36, 48–50]. In a review article, Boccaccio and Bruno
further emphasized the higher risk of anaemia in older
patients treated with TVR/PegIFN/R [51]. With respect to
rash, Smith et al., in a retrospective observational study,
indicated that actual body weight and BMI appear to be
related to rash development in patients treated with TVR/
PegIFN/R, and suggested that this finding may have
implications in the treatment of HCV with SMV/PegIFN/R
[52]. Roujeau et al. further reported that the incidence of
TVR-related dermatitis was significantly higher with age
[45 years, BMI\30 kg/m2, White race, and if receiving
therapy for HCV for the first time [53]. In a meta-analysis
performed by the Canadian Agency for Drugs and Tech-
nologies in Health, no consistent increased risk of rash was
found between BCP or TVR and SMV in treatment-expe-
rienced patients [54]. The ATTAIN head-to-head trial
further confirmed the superior safety profile of SMV/
PegIFN/R compared with TVR/PegIFN/R for anaemia,
pruritus and rash [9]; therefore limiting the extrapolation of
the risk profile of TVR/PegIFN/R to SMV/PegIFN/R as
suggested by Smith et al. Finally, this study shows also that
SVR12 achievers were more likely to be exposed to mul-
tiple adverse events and neutropenia. It is well acknowl-
edged that interferon (IFN) therapy causes a decrease in
neutrophil counts, as a result of bone marrow suppression
[55]. Retreatment of prior non-responders to PegIFN/R
with an IFN-based regimen increases their exposure to
IFN, potentially elevating the risk of neutropenia.
4.2 Differences Between SMV/PegIFN/R
and TVR/PegIFN/R
SMV/PegIFN/R was found to have a comparable impact on
total MRU-related costs to TVR/PegIFN/R, despite its
improved safety profile. This similarity in patterns of
MRU-related costs between the two treatment options
could be explained by factors other than the adverse events,
including the stronger impact of disease severity on costs,
the comparable efficacy between treatments, or by the fact
that potentially not all the medical services were captured
in this study.
Regarding the latter point, it should be noted that renal
dysfunction (not captured in our data) is recognized as a
side effect of TVR/PegIFN/R therapy [51, 56]. Identified
factors associated with renal impairment when treated with
TVR/PegIFN/R included advanced age and low initial
haemoglobin levels. On the other hand, creatinine clear-
ance was not found to influence pharmacokinetic parame-
ters of SMV/PegIFN/R in pharmacokinetic studies in
HCV-infected patients with mild to moderate renal
impairment treated with SMV/PegIFN/R [57]. Besides the
care services captured in the present study, an assessment
of resources required for the management of renal com-
plications could thus have been of interest. Not only that,
but also visits to dermatologists would have likely had an
impact on MRU-related costs given that patients treated
with TVR/PegIFN/R were exposed to a higher risk of
pruritus and rash. These resources were not specifically
captured in the clinical trial and thus were not included in
the analyses described above.
Though well recognized as a major component of the
overall care costs, the costs of drugs were not analysed in the
current study. The rationale behind this approach was that
there was no substantial difference in co-medication intake
(defined as the treatment length multiplied by the dose fre-
quency) and co-medication consumption (defined as the
treatment length multiplied by the dose frequency and the
unit of the dosage form—tablet/capsule or suspension)
between the two treatment arms (data not shown). More-
over, the main costs would be related to the drugs acting
directly against CHC, and these were also not different by
treatment arm due to the similar price levels of SMV and
TVR. Finally, this study primarily aims at identifying patient
and treatment characteristics that would influence non-drug
MRU-related costs, so that these could be better managed
via the implementation of efficient care programmes as
alternative routes so as to optimise clinical management and
generate additional savings. Focusing on utilization man-
agement approaches has also been proposed for the three
primary disease areas that account for the majority of the
specialty drug spending, including autoimmune disorders,
multiple sclerosis and cancer [58–60].
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The comparison of the level of MRU-related costs with
data from the literature was not evident given the lack of
data on MRU-related costs for prior non-responders to
PegIFN/R. However, our results aligned with the non-
drug-related costs of £806 reported by Backx et al. in
retreating non-SVR achievers with PegIFN/R; though the
following medical resources were captured: outpatient
clinic visits, HCV RNA tests, liver-related imaging, day-
case visits (e.g. endoscopy, liver biopsy) and inpatient
hospital stays [17]. In another study, the costs in Germany
were captured retrospectively. Stahmeyer et al. investi-
gated the following medical services: doctor visits, diag-
nostic and laboratory tests, pharmaceuticals and inpatient
care [13]. The mean outpatient cost (including diagnostic
procedures and excluding pharmaceuticals) was €1686.
The average inpatient cost was estimated at €1293.
Lastly, a Belgian study by Nevens et al. evaluated direct
medical costs on the basis of hospitalizations, day-clinic
visits, surgery/interventions, physician visits, and diag-
nostic tests and drug use over a 3-year follow-up period
[61]. Direct medical costs (hospitalization and ambulatory
care) were estimated at €3609 for patients with mild
CHC. Likewise, patients with moderate disease and cir-
rhosis without varices (abnormally dilated vessels) and
those with cirrhosis and varices had an average non-drug-
related cost of €3150 and of €6098, respectively. Con-
clusively, the direct comparison of MRU and MRU-re-
lated costs across these studies is challenging given
selected patient demographic and clinical characteristics,
study designs, treatment status (triple or dual PegIFN/R
regimens), type of response (treatment naı¨ve or experi-
enced), healthcare provision and cost structures. More-
over, in these studies, antiviral therapy included
exclusively PegIFN/R and thus did not include the effect
of a protease inhibitor like this study did.
Finally, this study showed that the adverse events were
significantly different between treatment arms and are
therefore relevant to consider when selecting between
treatment options for prior non-responders to PegIFN/R.
Owing to the more favourable safety profile [9], the
similar drug price levels and the comparable MRU-re-
lated non-drug costs of SMV/PegIFN/R as compared with
TVR/PegIFN/R, SMV/PegIFN/R could be suggested as
an alternative to TVR/PegIFN/R for treatment-experi-
enced patients, especially in national settings and in some
subgroups of patients where an IFN-based regimen might
still be used to limit the higher costs associated with an
IFN-free regimen; and/or when justifications of the risk/
benefit profile of antiviral combinations is required to
support the medically accepted indication and
reimbursement.
4.3 Strengths, Limitations and Future Directions
The multivariable OLS regression analysis predicted 9 % of
the variance in total MRU-related costs, indicating the
independent role played by age and interaction effects of
gender, F3–F4 and BLVL; and of BMI, F3–F4 and prior
response to PegIFN/R on total MRU-related costs patterns.
Additional research would be required to identify other
variables that could increase the predictive power of MRU
and related non-drug costs in treatment-experienced patients.
As previously mentioned, there may be additional
medical services, patient characteristics and treatment
features that were not captured in the present study and that
would have predicted substantial variance in total MRU-
related costs. Moreover, the current study does not capture
medication costs and laboratory tests but only the costs
associated with providing specific outpatient care and
hospitalization. Indirect costs were further not analysed.
The results from this study have strong implications for
policy makers, especially with the arrival of new antiviral
drugs and their combinations from late 2014 and beyond.
New regimens have been explored including the SMV/SOF
(sofosbuvir) combination, which was efficacious in null
responders and treatment-naı¨ve patients across all levels of
liver fibrosis, as well as in patients with the Q80K poly-
morphism [62]. SMV/SOF has further demonstrated effi-
cacy in patients with previous protease inhibitor failure,
despite retreatment comprising a protease inhibitor [63].
Prior non-responders are traditionally considered as a dif-
ficult group to treat and, because treatment for CHC began
as early as the 1990s, many of those living with HCV today
are considered treatment-experienced patients [64]. With
cure rates higher than 90 %, the difference between new
regimens and their effective and safe combination (in-
cluding decreased drug interactions, adverse events, side
effects and improved dosing regimens) will likely lie in the
ease of use (e.g. reduced pill burden), the shortened treat-
ment duration, costs and the high barrier to HCV resis-
tance. Access to care will then be an increasing point of
focus; hence the importance for policymakers to implement
early-stage curative strategies to avoid disease progression
and cost burden.
This study advocates the simultaneous monitoring of
liver disease severity and BLVL in special and difficult-to-
treat populations based on age, gender and BMI. Further
research is required to comprehend how patient demo-
graphics, clinical characteristics and treatment features of
IFN-free regimens in staged treatment alternatives would
improve non-drug-related savings and efficiency in care
delivery for PegIFN/R and proteinase inhibitor-experi-
enced patients.
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This study also has implications in national settings and in
some subgroups of patients where an IFN-based regimen
might still be used to limit the higher costs associated with an
IFN-free regimen, and/or when justifications of the risk/
benefit profile of antiviral combinations is required to sup-
port the medically accepted indication and reimbursement.
4.4 Conclusion and Clinical Implications
In this population of prior non-responders to PegIFN/R,
higher age and interaction effects between gender, F3–F4
METAVIR score and high BLVL; and between high BMI,
F3–F4 METAVIR stage and prior response to PegIFN/R
were found to be significantly associated with higher MRU-
related costs. In addition, F3–F4 METAVIR score was a
stronger predictor for costs than SVR12 in prior partial and
prior null responders to PegIFN/R. This suggests that by
starting treatment early, before CHC progresses, significant
treatment costs can be avoided. Moreover, weight loss
should further be encouraged in patients with CHC with a
high BMI to avoid additional costs.
Although there was no significant difference in costs
between treatment arms, SMV/PegIFN/R was associated
with a significantly lower likelihood of having adverse
events than TVR/PegIFN/R. This indicates that adverse
events are an important parameter to take into considera-
tion for the choice of treatment.
Acknowledgments The authors acknowledge Chris Corbett for his
advice on the manuscript.
Compliance with Ethical Standards
Conflict of interest The authors E. I. H. A. and J. K. declare no
conflict of interest. U. S. and G. W. are employees of Janssen Phar-
maceutica. All the analyses were performed by E. I. H. A. The
manuscript was written by E. I. H. A. and J. K. U. S. and G. W.
provided access to the simeprevir trial data and comments on the
manuscript. The study guarantor is U. S. All authors approved the
final version of the article. The authors have no other conflicts of
interest that are directly relevant to the content of this article.
Funding sources This study was sponsored by Janssen Pharma-
ceutica, which holds the market authorization of simeprevir.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin
Microbiol Infect. 2011;17(2):107–15.
2. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C
virus infection in USA: an estimate of true prevalence. Liver Int.
2011;31(8):1090–101.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.
Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
4. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Rou-
dot-Thoraval F. The burden of liver disease in Europe: a review
of available epidemiological data. J Hepatol. 2013;58(3):
593–608.
5. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von OJ, Lloyd AR,
et al. Estimating progression to cirrhosis in chronic hepatitis C
virus infection. Hepatology. 2001;34(4 Pt 1):809–16.
6. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I,
et al. Once-daily simeprevir (TMC435) with pegylated interferon
and ribavirin in treatment-naive genotype 1 hepatitis C: the ran-
domized PILLAR study. Hepatology. 2013;58(6):1918–29.
7. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky
VV, et al. Simeprevir with pegylated interferon alfa 2a plus rib-
avirin in treatment-naive patients with chronic hepatitis C virus
genotype 1 infection (QUEST-1): a phase 3, randomised, double-
blind, placebo-controlled trial. Lancet. 2014;384(9941):403–13.
8. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M,
Horsmans Y, et al. Simeprevir with pegylated interferon alfa 2a
or 2b plus ribavirin in treatment-naive patients with chronic
hepatitis C virus genotype 1 infection (QUEST-2): a randomised,
double-blind, placebo-controlled phase 3 trial. Lancet. 2014;
384(9941):414–26.
9. Reddy KR, Zeuzem S, Zoulim F, Weiland O, Horban A, Stanciu
C, et al. Simeprevir versus telaprevir with peginterferon and
ribavirin in previous null or partial responders with chronic
hepatitis C virus genotype 1 infection (ATTAIN): a randomised,
double-blind, non-inferiority phase 3 trial. Lancet Infect Dis.
2015;15(1):27–35.
10. Blatt C, da Cunha Bernardo N, Rosa J, Bagatini F, Alexandre R,
Neto G, et al. An estimate of the cost of hepatitis C treatment for
the Brazilian health system. Value Health Reg Issues.
2012;1:129–35.
11. Sa´nchez-A´vila J. Cost efficacy and cost-benefit of treatment of
hepatitis C. Ann Hepatol. 2006;5(Suppl. 1):S69–73.
12. Stahmeyer JT, Rossol S, Bert F, Abdelfattah AM, Mauss S,
Heyne R, et al. Epidemiology, treatment outcomes and costs of
treating hepatitis C in routine care—results from a large multi-
center trial. Value Health. 2013;16(7):A341–2.
13. Stahmeyer JT, Rossol S, Bert F, Antoni C, Demir M, Hinrichsen
H, et al. Cost of treating hepatitis C in Germany: a retrospective
multicenter analysis. Eur J Gastroenterol Hepatol. 2014;26(11):
1278–85.
14. Su J, Brook RA, Kleinman NL, Corey-Lisle P. The impact of
hepatitis C virus infection on work absence, productivity, and
healthcare benefit costs. Hepatology. 2010;52(2):436–42.
15. Chronic conditions: making the case for ongoing care. Partner-
ship for Solutions. Johns Hopkins University for The Robert
Wood Johnson Foundation; 2002.
16. Yu W, Ravelo A, Wagner TH, Phibbs CS, Bhandari A, Chen S,
et al. Prevalence and costs of chronic conditions in the VA health
care system. Med Care Res Rev. 2003;60(3 Suppl):146S–67S.
17. Backx M, Lewszuk A, White JR, Cole J, Sreedharan A, van
Sanden S, et al. The cost of treatment failure: resource use and
costs incurred by hepatitis C virus genotype 1-infected patients
who do or do not achieve sustained virological response to
therapy. J Viral Hepat. 2014;21(3):208–15.
18. Manos MM, Darbinian J, Rubin J, Ray GT, Shvachko V, Denis
B, et al. The effect of hepatitis C treatment response on medical
costs: a longitudinal analysis in an integrated care setting.
J Manag Care Pharm. 2013;19(6):438–47.
Direct Medical Costs for HCV Infection 347
19. Department of Health. Reference costs 2011–12. National Health
Services; 2012.
20. Curtis L, Netten A. Unit costs of health and social care 2008.
Canterbury: The University of Kent, Personal Social Services
Research Unit; 2008.
21. Curtis L. Unit costs of health and social care 2007. Canterbury:
University of Kent, Personal Social Services Research Unit;
2007.
22. Office for National Statistics. Consumer Price Inflation Reference
Tables, March 2013. UK Statistics Authority 2013. http://www.ons.
gov.uk/ons/rel/cpi/consumer-price-indices/march-2013/consumer-
price-inflation-reference-tables.xls. Accessed 16 May 2013.
23. Thompson SG, Barber JA. How should cost data in pragmatic
randomised trials be analysed? BMJ. 2000;320(7243):1197–200.
24. Efron B, Tibshirani RJ. An introduction to the bootstrap. New
York: CRC press; 1993.
25. Daggy JK, Thomas J III, Craig BA. Modeling correlated
healthcare costs. Expert Rev Pharmacoecon Outcomes Res.
2011;11(1):101–11.
26. Gordon SC, Pockros PJ, Terrault NA, Hoop RS, Buikema A,
Nerenz D, et al. Impact of disease severity on healthcare costs in
patients with chronic hepatitis C (CHC) virus infection. Hepa-
tology. 2012;56(5):1651–60.
27. Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T,
et al. Chronic hepatitis C virus (HCV) disease burden and cost in
the United States. Hepatology. 2013;57(6):2164–70.
28. Kirk GD, Mehta SH, Astemborski J, Galai N, Washington J,
Higgins Y, et al. HIV, age, and the severity of hepatitis C virus-
related liver disease: a cohort study. Ann Intern Med.
2013;158(9):658–66.
29. Taura N, Yatsuhashi H, Hamasaki K, Nakao K, Daikoku M, Ueki
T, et al. Increasing hepatitis C virus-associated hepatocellular
carcinoma mortality and aging: long term trends in Japan.
Hepatol Res. 2006;34(2):130–4.
30. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis
progression in patients with chronic hepatitis C. The OBSVIRC,
METAVIR, CLINIVIR, and DOSVIRC groups. Lancet.
1997;349(9055):825–32.
31. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis,
management, and treatment of hepatitis C: an update. Hepatol-
ogy. 2009;49(4):1335–74.
32. Gramenzi A, Conti F, Felline F, Cursaro C, Riili A, Salerno M,
et al. Hepatitis C Virus-related chronic liver disease in elderly
patients: an Italian cross-sectional study. J Viral Hepat.
2010;17(5):360–6.
33. Kim HI, Kim IH, Jeon BJ, Lee S, Kim SH, Kim SW, et al. Treat-
ment response and tolerability of pegylated interferon-alpha plus
ribavirin combination therapy in elderly patients ([/=65 years)
with chronic hepatitis C in Korea. Hepat Mon. 2012;12(7):430–6.
34. Aapro MS, Cella D, Zagari M. Age, anemia, and fatigue. Semin
Oncol. 2002;29(3 Suppl 8):55–9.
35. Dan AA, Martin LM, Crone C, Ong JP, Farmer DW, Wise T,
et al. Depression, anemia and health-related quality of life in
chronic hepatitis C. J Hepatol. 2006;44(3):491–8.
36. Bichoupan K, Schwartz JM, Martel-Laferriere V, Giannattasio
ER, Marfo K, Odin JA, et al. Effect of fibrosis on adverse events
in patients with hepatitis C treated with telaprevir. Aliment
Pharmacol Ther. 2014;39(2):209–16.
37. Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Oshita M,
Hagiwara H, et al. Indications and limitations for aged patients
with chronic hepatitis C in pegylated interferon alfa-2b plus
ribavirin combination therapy. J Hepatol. 2011;54(4):604–11.
38. Colombo M, Strasser SI, Moreno C, Ferreira PA, Urbanek P,
Fernandez I, et al. Sustained virological response with telaprevir
in 1078 patients with advanced hepatitis C: the International
Telaprevir Access Program. J Hepatol. 2014;61(5):976–83.
39. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Sch-
lecker C, et al. Importance of IL28B gene polymorphisms in
hepatitis C virus genotype 2 and 3 infected patients. J Hepatol.
2011;54(3):415–21.
40. Sugawara Y, Tamura S, Kokudo N. Antiviral treatment for
hepatitis C virus infection after liver transplantation. Hepat Res
Treat. 2010;2010:475746.
41. Dale CH, Burns P, McCutcheon M, Hernandez-Alejandro R,
Marotta PJ. Spontaneous clearance of hepatitis C after liver and
renal transplantation. Can J Gastroenterol. 2009;23(4):265–7.
42. Samonakis DN, Cholongitas E, Triantos CK, Griffiths P, Dhil-
lon AP, Thalheimer U, et al. Sustained, spontaneous disap-
pearance of serum HCV-RNA under immunosuppression after
liver transplantation for HCV cirrhosis. J Hepatol. 2005;
43(6):1091–3.
43. Wiesner RH, Sorrell M, Villamil F. Report of the first Interna-
tional Liver Transplantation Society expert panel consensus
conference on liver transplantation and hepatitis C. Liver Transpl.
2003;9(11):S1–9.
44. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and
liver transplantation. J Hepatol. 2001;35(5):666–78.
45. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Short-
house C, Clouston A, et al. Fibrosis in chronic hepatitis C cor-
relates significantly with body mass index and steatosis.
Hepatology. 1999;29(4):1215–9.
46. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body
mass index is an independent risk factor for nonresponse to
antiviral treatment in chronic hepatitis C. Hepatology. 2003;
38(3):639–44.
47. Hickman IJ, Powell EE, Prins JB, Clouston AD, Ash S, Purdie
DM, et al. In overweight patients with chronic hepatitis C, cir-
culating insulin is associated with hepatic fibrosis: implications
for therapy. J Hepatol. 2003;39(6):1042–8.
48. Singh G, Issa D, Sedki E, Hanouneh I, Lopez R, Zein N, et al.
Anemia in patients with chronic hepatitis C infection during triple
therapy with telaprevir or boceprevir—a controlled study. J An-
tivir Antiretrovir. 2013;5:173–7.
49. Colombo M, Fernandez I, Abdurakhmanov D, Ferreira PA,
Strasser SI, Urbanek P, et al. Safety and on-treatment efficacy of
telaprevir: the early access programme for patients with advanced
hepatitis C. Gut. 2014;63(7):1150–8.
50. Akpo EI, Cerri K, Kleintjens J. Predicting the impact of adverse
events and treatment duration on medical resource utilization-
related costs in hepatitis C genotype 1 treatment-naive patients
receiving antiviral therapy. Pharmacoeconomics. 2015;33(4):
409–22.
51. Boccaccio V, Bruno S. Optimal management of patients with
chronic hepatitis C and comorbidities. Liver Int. 2015;35(Suppl
1):35–43.
52. Smith MA, Johnson HJ, Chopra KB, Dunn MA, Ulrich AM,
Mohammad RA. Incidence and management of rash in telaprevir-
treated patients. Ann Pharmacother. 2014;48(9):1166–71.
53. Roujeau JC, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC,
Harding M, et al. Telaprevir-related dermatitis. JAMA Dermatol.
2013;149(2):152–8.
54. Canadian Agency for Drugs and Technology in Health. CADTH
therapeutic review. Direct-acting antiviral agents for chronic
hepatitis C Genotype 1. 2014. http://www.cadth.ca/media/pdf/
TR0007_HepC_RecsReport_e.pdf. Accessed 1 Mar 2015.
55. Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K,
et al. Neutropenia during combination therapy of interferon alfa
and ribavirin for chronic hepatitis C. Hepatology. 2002;36(5):
1273–9.
56. Karino T, Ozeki I, Hige S, Kimura M, Arakawa T, Nakajima T,
et al. Telaprevir impairs renal function and increases blood rib-
avirin concentration during telaprevir/pegylated interferon/
348 E. I. H. Akpo et al.
ribavirin therapy for chronic hepatitis C. J Viral Hepat.
2014;21(5):341–7.
57. Mauss S, Buti M, Moreno C, Foster GR, DeMasi R, Baldini A
et al. Renal function in HCV genotype 1-infected treatment-naı¨ve
patients receiving simeprevir in combination with Peg-IFN and
ribavirin: a post-hoc analysis. J.Viral Hepat. 2014;21.
58. Kenney JT Jr. Payers’ management of oncology drugs: opportu-
nities and challenges. Am Health Drug Benefits. 2014;7(3):123–4.
59. DaCosta BS, Nash SE, Mytelka D, Bowman L, Teitelbaum A.
Healthcare costs, treatment patterns, and resource utilization
among pancreatic cancer patients in a managed care population.
J Med Econ. 2013;16(12):1379–86.
60. Miller MK, Lee JH, Blanc PD, Pasta DJ, Gujrathi S, Barron H,
et al. TENOR risk score predicts healthcare in adults with severe
or difficult-to-treat asthma. Eur Respir J. 2006;28(6):1145–55.
61. Nevens F, Colle I, Michielsen P, Robaeys G, Moreno C,
Caekelbergh K, et al. Resource use and cost of hepatitis C-related
care. Eur J Gastroenterol Hepatol. 2012;24(10):1191–8.
62. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, You-
nossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with
or without ribavirin, to treat chronic infection with hepatitis C
virus genotype 1 in non-responders to pegylated interferon and
ribavirin and treatment-naive patients: the COSMOS randomised
study. Lancet. 2014;384(9956):1756–65.
63. Dusheiko G. Controlling hepatitis C with simeprevir. Lancet
Infect Dis. 2015;15(1):2–4.
64. Welch NM, Jensen DM. Pegylated interferon based therapy with
second-wave direct-acting antivirals in genotype 1 chronic hep-
atitis C. Liver Int. 2015;35(Suppl. 1):11–7.
Direct Medical Costs for HCV Infection 349
